It’s been about 810 days since Starpharma teased the market with this statement in an ASX announcement regarding the DEP-Cabazitaxel Phase 2 data:
’Data from this cohort of prostate cancer patients is being presented in confidential commercial discussions with several potential pharmaceutical companies / partners.’
How embarrassing and truly disappointing that nothing has come of this.
It’s been apparent for years that the once flagship DEP-Docetaxel was sliding down the pecking order and is now IMO dud status.
Is there any hope for the other two in-house drugs being trialled? Well it’s looking less likely by the day.
Help us AstraZeneca, you’re our only hope.
P.S. What’s with all the covid Twitter spam on the other thread? It comes off as majorly desperate.
